You are here

Production of Inactivated Vaccines Using Supralethal Irradiation

Award Information
Agency: Department of Defense
Branch: Defense Threat Reduction Agency
Contract: HDTRA1-17-C-0030
Agency Tracking Number: T2-0243
Amount: $990,021.00
Phase: Phase II
Program: STTR
Solicitation Topic Code: DTRA14B-002
Solicitation Number: 14.B
Solicitation Year: 2014
Award Year: 2017
Award Start Date (Proposal Award Date): 2017-06-22
Award End Date (Contract End Date): 2019-06-25
Small Business Information
124 BYte Drive
Frederick, MD 21702
United States
DUNS: 944050277
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Gregory J Tobin
 Chief Scientific Officer
 (301) 471-0201
Business Contact
 Gregory Tobin
Phone: (301) 471-0201
Research Institution
 Henry M. Jackson Foundation for the Advancement of Military Medicine
 Marta Krzywucki Marta Krzywucki
6720A Rockledge Dr #100
Rockville, MD 20817
United States

 (301) 295-3451
 Nonprofit College or University

The discovery and commercial development of licensed vaccines often take many years of research followed by years of pre-clinical and clinical development. We propose to assess the feasibility of using a novel irradiation-inactivation technology to develop vaccines more rapidly. The technology utilizes a manganese-peptide complex to protect antigenic proteins from ionizing radiation while allowing the nucleic acid genome to be destroyed. In the Phase I, we demonstrated the feasibility of the method using poliovirus (PV1-Sabin). All objectives of the Phase I were met or exceeded. In the Phase II, we propose to continue the development of an improved trivalent inactivated polio vaccine and test the technology against a bacterial target. The improvements to the polio vaccine include (1) the use of attenuated Sabin strains to improve biosafety profiles and (2) a reduced cost due to improved immunogenicity as compared to existing chemically-inactivated vaccines (IPV). At each stage of development, the improved vaccine candidate will be tested for stimulation of neutralizing antibodies in the accepted animal model. We also propose to expand the study to include the antibiotic-resistant bacteria, Acinetobacter baumannii, using mouse models of lung and wound infection.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government